The U.S. Food and Drug Administration (FDA) has long encountered the combination of promise, risk, and uncertainty that accompanies new technologies. This is equally true for nanotechnology, which engenders both excitement and concern owing to the rapidly evolving science and range of applications. The very changes in biological, chemical, and other properties that make some applications so exciting may also present new questions about how to predict, identify, measure, and monitor possibly harmful effects.
